Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superio...
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Wiley
2021-07-01
|
| Collection: | Journal of Diabetes Investigation |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1111/jdi.13457 |